Literature DB >> 25712967

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.

Patricia L Winokur1, Shital M Patel2, Rebecca Brady3, Wilbur H Chen4, Samer S El-Kamary4, Kathryn Edwards5, C Buddy Creech5, Sharon Frey6, Wendy A Keitel7, Robert Belshe6, Emmanuel Walter8, Abbie Bellamy9, Heather Hill9.   

Abstract

Influenza A(H5N1) vaccination strategies that improve the speed of the immunological response and cross-clade protection are desired. We compared the immunogenicity of a single 15-μg or 90-μg dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine in adults who were previously primed with A/H5N1/Vietnam/1203/2004 (clade 1) vaccine. High-dose vaccine resulted in significantly higher titers to both clade 1 and 2 antigens. Clade 2 titers were unaffected by the previous dose of clade 1 vaccine. Low-dose priming with a mismatched pandemic influenza A(H5N1) vaccine would improve the rapidity, magnitude, and cross-reactivity of the immunological response following a single high-dose, unadjuvanted, pandemic vaccine.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  H5N1; influenza; prime-boost; vaccine

Mesh：

Substances：

Year:  2015        PMID： 25712967      PMCID： PMC4598805          DOI： 10.1093/infdis/jiv087

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  Variable efficacy of repeated annual influenza vaccination.

Authors:  D J Smith; S Forrest; D H Ackley; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza.

Authors:  Nimalan Arinaminpathy; Oliver Ratmann; Katia Koelle; Suzanne L Epstein; Graeme E Price; Cecile Viboud; Mark A Miller; Bryan T Grenfell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-07       Impact factor: 11.205

3.  Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Authors:  Grazia Galli; Kathy Hancock; Katja Hoschler; Joshua DeVos; Michaela Praus; Monia Bardelli; Carmine Malzone; Flora Castellino; Chiara Gentile; Teresa McNally; Giuseppe Del Giudice; Angelika Banzhoff; Volker Brauer; Emanuele Montomoli; Maria Zambon; Jacqueline Katz; Karl Nicholson; Iain Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-27       Impact factor: 11.205

Review 4.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

5.  Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

Authors:  Tino F Schwarz; Thomas Horacek; Markus Knuf; Hanns-Gerd Damman; François Roman; Mamadou Dramé; Paul Gillard; Wolfgang Jilg
Journal:  Vaccine       Date:  2009-10-23       Impact factor: 3.641

6.  Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.

Authors:  Robert B Belshe; Sharon E Frey; Irene Graham; Mark J Mulligan; Srilatha Edupuganti; Lisa A Jackson; Anna Wald; Gregory Poland; Robert Jacobson; Harry L Keyserling; Paul Spearman; Heather Hill; Mark Wolff
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

7.  Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Authors:  Iain Stephenson; Roberto Bugarini; Karl G Nicholson; Audino Podda; John M Wood; Maria C Zambon; Jacqueline M Katz
Journal:  J Infect Dis       Date:  2005-03-14       Impact factor: 5.226

8.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

9.  Mitigation strategies for pandemic influenza in the United States.

Authors:  Timothy C Germann; Kai Kadau; Ira M Longini; Catherine A Macken
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

10.  Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature.

Authors: 
Journal:  Influenza Other Respir Viruses       Date:  2011-10-29       Impact factor: 4.380
View more
  9 in total

1.  An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition.

Authors:  Enitra N Jones; Samuel Amoah; Weiping Cao; Suryaprakash Sambhara; Shivaprakash Gangappa
Journal:  J Infect Dis       Date:  2017-09-15       Impact factor: 5.226

2.  Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults.

Authors:  Joon Young Song; Min Joo Choi; Ji Yun Noh; Won Suk Choi; Hee Jin Cheong; Seong-Heon Wie; Jin-Soo Lee; Gyu-Jin Woo; Sang Ho Lee; Woo Joo Kim
Journal:  Hum Vaccin Immunother       Date:  2016-12-20       Impact factor: 3.452

3.  Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Authors:  Innocent N Mbawuike; Robert L Atmar; Shital M Patel; David B Corry; Patricia L Winokur; Rebecca C Brady; Wilbur H Chen; Kathryn M Edwards; C Buddy Creech; Emmanuel B Walter; Sharon E Frey; Robert B Belshe; Johannes B Goll; Heather Hill; Wendy A Keitel
Journal:  Vaccine       Date:  2015-12-04       Impact factor: 3.641

4.  Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.

Authors:  Daniel F Hoft; Kathleen Lottenbach; Johannes B Goll; Heather Hill; Patricia L Winokur; Shital M Patel; Rebecca C Brady; Wilbur H Chen; Kathryn Edwards; C Buddy Creech; Sharon E Frey; Tamara P Blevins; Rachelle Salomon; Robert B Belshe
Journal:  J Infect Dis       Date:  2016-07-20       Impact factor: 5.226

5.  Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.

Authors:  Leora R Feldstein; Laura Matrajt; M Elizabeth Halloran; Wendy A Keitel; Ira M Longini
Journal:  Vaccine       Date:  2016-06-20       Impact factor: 3.641

6.  Refining the approach to vaccines against influenza A viruses with pandemic potential.

Authors:  Rita Czako; Kanta Subbarao
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

7.  Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.

Authors:  Patricia Winokur; Hana M El Sahly; Mark J Mulligan; Sharon E Frey; Richard Rupp; Evan J Anderson; Kathryn M Edwards; David I Bernstein; Kenneth Schmader; Lisa A Jackson; Wilbur H Chen; Heather Hill; Abigail Bellamy
Journal:  Vaccine       Date:  2021-01-21       Impact factor: 3.641

8.  Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies.

Authors:  Rie Nakajima; Medalyn Supnet; Algis Jasinskas; Aarti Jain; Omid Taghavian; Joshua Obiero; Donald K Milton; Wilbur H Chen; Michael Grantham; Richard Webby; Florian Krammer; Darrick Carter; Philip L Felgner; D Huw Davies
Journal:  mSphere       Date:  2018-12-12       Impact factor: 4.389

Review 9.  Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review.

Authors:  Adinda Kok; Ron A M Fouchier; Mathilde Richard
Journal:  Vaccines (Basel)       Date:  2021-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.